Brind.

FDA granted Fast Track designation for Verve-102 on July 11, 2025, coinciding with Lilly's acquisition announcement that surged Verve's stock.

5 reports, 1 independent Updated Jul 11

Gone quiet

Reports: 5
Developments: 2
Repetition: 60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA granted Fast Track designation for Verve-102 on July 11, 2025, coinciding with Lilly's acquisition announcement that surged Verve's stock.

Who's involved

What this event is mainly about

Verve Therapeutics FDA Eli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.

Jul 11FDA granted Fast Track for Verve-102; Lilly's acquisition announcement surged Verve's stock.1 source
- Insider Monkey
Jul 2Lilly is pursuing an acquisition of Verve Therapeutics, while major players navigate strategic M&A deals and FDA shifts.

Keep exploring

The entities involved

Verve Therapeutics
American pharmaceutical company

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Related events

Coverage

Newest first; wire copies grouped

Jul 11Insider MonkeyVerve Therapeutics, Inc. (VERV): A Bull Case Theory We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize
Jul 8Unknown outlet
Jul 2Unknown outlet
Jun 27Unknown outlet
Jun 21Unknown outlet